Estimating the potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study
Rebecca A. Clark , Allison Portnoy , Chathika K. Weerasuriya , Tom Sumner , Roel Bakker , Rebecca C. Harris , Kirankumar Rade , Sanjay Kumar Mattoo , Dheeraj Tumu , Nicolas A. Menzies , Richard G. White
{"title":"Estimating the potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study","authors":"Rebecca A. Clark , Allison Portnoy , Chathika K. Weerasuriya , Tom Sumner , Roel Bakker , Rebecca C. Harris , Kirankumar Rade , Sanjay Kumar Mattoo , Dheeraj Tumu , Nicolas A. Menzies , Richard G. White","doi":"10.1016/j.lansea.2024.100424","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>India has the largest tuberculosis burden, but the all-age prevalence in 2021 ranged from 747/100,000 in Delhi to 137/100,000 in Gujarat. No modelling studies have compared the potential impact of new tuberculosis vaccines in regions with differing disease and infection prevalence.</div></div><div><h3>Methods</h3><div>We used modelling to simulate hypothetical scenarios of introducing M72/AS01<sub>E</sub> (with 50% efficacy to prevent disease) and BCG-revaccination (with 45% efficacy to prevent infection) in Delhi and Gujarat.</div></div><div><h3>Findings</h3><div>The hypothetical M72/AS01<sub>E</sub> scenario could avert 16.0% of cases and 14.4% of deaths in Delhi, and 8.5% of cases and 7.6% of deaths in Gujarat between 2025 and 2050. The hypothetical BCG-revaccination scenario could avert 8.8% of cases and 8.3% of deaths in Delhi, and 5.1% of cases and 4.8% of deaths in Gujarat between 2025 and 2050.</div></div><div><h3>Interpretation</h3><div>Additional trials for both vaccines are underway, which will provide further evidence on the vaccine efficacy and narrow the range of uncertainty on the estimates.</div></div><div><h3>Funding</h3><div><span>Bill & Melinda Gates Foundation</span> (INV-001754).</div></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":"31 ","pages":"Article 100424"},"PeriodicalIF":5.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet regional health. Southeast Asia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277236822400074X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background
India has the largest tuberculosis burden, but the all-age prevalence in 2021 ranged from 747/100,000 in Delhi to 137/100,000 in Gujarat. No modelling studies have compared the potential impact of new tuberculosis vaccines in regions with differing disease and infection prevalence.
Methods
We used modelling to simulate hypothetical scenarios of introducing M72/AS01E (with 50% efficacy to prevent disease) and BCG-revaccination (with 45% efficacy to prevent infection) in Delhi and Gujarat.
Findings
The hypothetical M72/AS01E scenario could avert 16.0% of cases and 14.4% of deaths in Delhi, and 8.5% of cases and 7.6% of deaths in Gujarat between 2025 and 2050. The hypothetical BCG-revaccination scenario could avert 8.8% of cases and 8.3% of deaths in Delhi, and 5.1% of cases and 4.8% of deaths in Gujarat between 2025 and 2050.
Interpretation
Additional trials for both vaccines are underway, which will provide further evidence on the vaccine efficacy and narrow the range of uncertainty on the estimates.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
